Endofaster Robot for Gastroesophageal Submucosal Tumors: A Randomized Controlled Study
2026年6月17日 更新者:The First Affiliated Hospital of Soochow University
Effectiveness and Safety of the Endofaster Surgical Robot System for Precise Dissection of Gastroesophageal Submucosal Tumors: A Single-Center Randomized Controlled Study
In endoscopic treatment for gastric submucosal tumors arising from the muscularis propria, does robot-assisted surgery yield a higher serosa preservation rate, shorter operative time and lower complication rates than conventional endoscopic procedures?
研究概览
详细说明
For endoscopic treatment of gastric submucosal tumors originating from the muscularis propria, this study aims to explore whether robot-assisted therapy can improve serosa preservation rate, shorten operative time and reduce complications compared with conventional endoscopic surgery.
研究类型
介入性
注册 (估计的)
110
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Chenhuan Tan
- 电话号码:+86 18860928860
- 邮箱:tanchenhuan2013@163.com
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
描述
Inclusion Criteria:
- Aged 18 to 80 years old;
- Submucosal tumors originating from the muscularis propria of gastric fundus, highly suspected as gastrointestinal stromal tumor (GIST) confirmed by endoscopic ultrasonography (EUS) and contrast-enhanced computed tomography (CT);
- Tumor diameter ranging from 1.0 cm to 3.0 cm;
- No active ulcer or bleeding on the lesion surface before operation;
- American Society of Anesthesiologists (ASA) physical status class I-III;
- Voluntarily signed written informed consent.
Exclusion Criteria:
- Tumor adhesion to serosa with unclear interface shown on EUS;
- High-risk GIST or distant metastasis indicated by imaging or endoscopy;
- History of gastric surgery or radiotherapy;
- High bleeding risk including coagulation disorders and patients unable to discontinue anticoagulant medications;
- Pregnant or breastfeeding women;
- Failure to cooperate with follow-up.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:RG(Robot group)
1.Marking and mucosal incision.2.Grasp the tumor or its pedicle with the robotic flexible arm, apply continuous and steady traction toward the luminal side to dynamically expose the anatomical space between the tumor capsule and normal muscular layer.3.Perform meticulous dissection along the capsule-muscular layer interface using an ESD knife, and preserve the integrity of the serosa as much as possible.4.En bloc resection and removal of the tumor.5.Verification of serosal integrity: The procedure can be completed only if air/water insufflation test shows negative results.
Mucosal defects are closed by standard techniques.
|
After Marking and mucosal incision,Grasp the tumor or its pedicle with the robotic flexible arm, apply continuous and steady traction toward the luminal side to dynamically expose the anatomical space between the tumor capsule and normal muscular layer.
|
|
有源比较器:TG(Traditional Group)
The procedures are performed by surgeons of equivalent seniority via conventional endoscopic full-thickness resection (EFTR) or modified endoscopic submucosal dissection (modified ESD).
If a safe dissection plane cannot be established, full-thickness incision is conducted followed by closure using over-the-scope clip (OTSC), covered stent or suturing techniques.
Leakage is assessed and managed in accordance with standard protocols.
|
Conventional endoscopy without Robot
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Serosa integrity rate
大体时间:perioperative
|
En bloc resection rate with serosa preserved
|
perioperative
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Duration of the surgical procedure
大体时间:Intraoperative
|
Total duration of the surgical procedure
|
Intraoperative
|
|
Dissection time
大体时间:perioperative
|
Dissection time of tumor
|
perioperative
|
|
Intraoperative blood loss
大体时间:perioperative
|
Intraoperative blood loss during surgury
|
perioperative
|
|
Postoperative fever rate
大体时间:Within 7 days after surgery
|
Postoperative fever is defined as a body temperature ≥ 37.5 ℃ within 7 days after surgery.
All febrile cases during this period are included, including non-infectious absorption fever.
|
Within 7 days after surgery
|
|
Postoperative infection
大体时间:Within 30 days after surgery
|
Postoperative infection is diagnosed when body temperature reaches ≥ 38.5 ℃, or temperature ≥ 38.0 ℃ persists for more than 3 consecutive days starting from postoperative day 3. Diagnosis shall be confirmed by clinical symptoms, abnormal laboratory inflammatory indicators or positive microbial culture results.
Simple absorption fever is excluded.
|
Within 30 days after surgery
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Rui Li、The First Affiliated Hospital of Soochow University
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (估计的)
2026年7月1日
初级完成 (估计的)
2027年12月31日
研究完成 (估计的)
2028年6月30日
研究注册日期
首次提交
2026年6月13日
首先提交符合 QC 标准的
2026年6月17日
首次发布 (实际的)
2026年6月18日
研究记录更新
最后更新发布 (实际的)
2026年6月18日
上次提交的符合 QC 标准的更新
2026年6月17日
最后验证
2026年6月1日
更多信息
与本研究相关的术语
其他研究编号
- 2026250
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
是的
IPD 计划说明
The shared datasets cover all collected de-identified individual participant data related to this trial, such as demographic data, imaging findings, surgical data, complication records and pathological results.
No personal identifiable information will be retained.
Data will be available to qualified researchers for legitimate scientific research use.
IPD 共享时间框架
Beginning 6 months after publication of study results and ending 2 years thereafter
IPD 共享访问标准
Access is limited to qualified researchers for legitimate scientific research purposes.
All de-identified IPD and selected supporting documents are available.
Researchers need to submit a formal application, and data will be provided upon approval.
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
- 分析代码
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.